Testing to discontinue imatinib already started some years after the advent of this new CML therapy. Since that time, despite many trials and studies in this field, there are still significant gaps, and many fundamental questions remain unanswered. Probably the most intriguing is the persistence of minimal residual disease, which does not lead to disease recurrence in all patients. Nevertheless, today's understanding enables TKI to be safely discontinued in eligible patients outside clinical trials. Notwithstanding, TKI cessation still has to be considered and indicated with caution, taking into account several important viewpoints, like: (i) why stop the therapy in a particular patient, and are all the eligible patients willing to cease the treatment? (ii) Will all the TKI-related side effects relieve upon stopping? (iii) are there any side effects after discontinuing treatment? This review covers extensively all aspects of treatment cessation, like history, theoretical background, eligible patients, monitoring after treatment discontinuation, trigger for retreatment, therapy restart, predictive factors for successful therapy cessation, immunological aspects, potential complications of TKI withdrawal, late molecular relapses, blast crisis development, kinetics of preexisting TKI-related side effects and laboratory values, and quality of life upon treatment cessation. The art of treatment cessation is to select the best candidate based on many diverse facts and information, and follow the patient in the most rational way with smartly anticipating the potential risks and side effects.

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Karanas A. and Silver R. T., “Characteristics of the Terminal Phase of Chronic Granulocytic Leukemia,” Blood 32, no. 3 (1968): 445–459, 10.1182/blood.v32.3.445.445. PubMed DOI

Baccarani M., Saglio G., Goldman J., et al. “European Leukemianet. Evolving Concepts in the Management of Chronic Myeloid Leukemia: Recommendations From an Expert Panel on Behalf of the European Leukemianet,” Blood 108, no. 6 (2006): 1809–1820, 10.1182/blood-2006-02-005686. PubMed DOI

Baccarani M., Russo D., Rosti G., and Martinelli G., “Interferon‐Alfa for Chronic Myeloid Leukemia,” Seminars in Hematology 40, no. 1 (2003): 22–33, 10.1016/s0037-1963(03)70040-7. PubMed DOI

O'Brien S. G., Guilhot F., Larson R. A., et al. “Imatinib Compared With Interferon and Low‐Dose Cytarabine for Newly Diagnosed Chronic‐Phase Chronic Myeloid Leukemia,” New England Journal of Medicine 348, no. 11 (2003): 994–1004, 10.1056/nejmoa022457. PubMed DOI

Hochhaus A., Larson R. A., Guilhot F., et al. “Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia,” New England Journal of Medicine 376, no. 10 (2017): 917–927, 10.1056/nejmoa1609324. PubMed DOI PMC

Apperley J. F., Milojkovic D., Cross N. C. P., et al. “2025 European Leukemianet Recommendations for the Management of Chronic Myeloid Leukemia,” Leukemia 39, no. 8 (2025): 1797–1813, 10.1038/s41375-025-02664-w. PubMed DOI PMC

Talpaz M., Kurzrock R., O’Brien S., and Kantarjian H., “Unmaintained Complete Remission (Cures?) Among Interferon Treated Philadelphia Positive Chronic Myelogenous Leukemia (CML Ph

Mahon F. X., Delbrel X., Cony‐Makhoul P., et al. “Follow‐Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa,” Journal of Clinical Oncology 20, no. 1 (2002): 214–220, 10.1200/jco.2002.20.1.214. PubMed DOI

Cortes J., O'Brien S., and Kantarjian H., “Discontinuation of Imatinib Therapy After Achieving a Molecular Response,” Blood 104, no. 7 (2004): 2204–2205, 10.1182/blood-2004-04-1335. PubMed DOI

Mauro M. J., Druker B. J., and Maziarz R. T., “Divergent Clinical Outcome in Two CML Patients Who Discontinued Imatinib Therapy After Achieving a Molecular Remission,” Leukemia Research 28, no. 1 (2004): S71–S73, 10.1016/j.leukres.2003.10.017. PubMed DOI

Merante S., Orlandi E., Bernasconi P., Calatroni S., Boni M., and Lazzarino M., “Outcome of Four Patients With Chronic Myeloid Leukemia After Imatinib Mesylate Discontinuation,” Haematologica 90, no. 7 (2005): 979–981, https://haematologica.org/article/view/3597. PubMed

Rousselot P., Huguet F., Rea D., et al. “Imatinib Mesylate Discontinuation in Patients With Chronic Myelogenous Leukemia in Complete Molecular Remission for More Than 2 Years,” Blood 109, no. 1 (2007): 58–60, 10.1182/blood-2006-03-011239. PubMed DOI

Mahon F. X., Pfirrmann M., Dulucq S., et al. “European Stop Tyrosine Kinase Inhibitor Trial (EURO‐SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment‐Free Remission,” Journal of Clinical Oncology 42, no. 16 (2024): 1875–1880, 10.1200/jco.23.01647. PubMed DOI

Saussele S., Richter J., Guilhot J., et al. “Discontinuation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia (EURO‐SKI): A Prespecified Interim Analysis of a Prospective, Multicentre, Non‐Randomised, Trial,” Lancet Oncology 19, no. 6 (2018): 747–757, 10.1016/s1470-2045(18)30192-x. PubMed DOI

Shah N. P., García‐Gutiérrez V., Jiménez‐Velasco A., et al. “Treatment‐Free Remission After Dasatinib in Patients With Chronic Myeloid Leukaemia in Chronic Phase With Deep Molecular Response: Final 5‐Year Analysis of DASFREE,” British Journal of Haematology 202, no. 5 (2023): 942–952, 10.1111/bjh.18883. PubMed DOI PMC

Shah N. P., García‐Gutiérrez V., Jiménez‐Velasco A., et al. “Dasatinib Discontinuation in Patients With Chronic‐Phase Chronic Myeloid Leukemia and Stable Deep Molecular Response: The DASFREE Study,” Leukemia and Lymphoma 61, no. 3 (2020): 650–659, 10.1080/10428194.2019.1675879. PubMed DOI

Haddad F. G., Sasaki K., Issa G. C., et al. “Treatment‐Free Remission in Patients With Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors,” American Journal of Hematology 97, no. 7 (2022): 856–864, 10.1002/ajh.26550. PubMed DOI PMC

Hughes T. P., Clementino N. C. D., Fominykh M., et al. “Long‐Term Treatment‐Free Remission in Patients With Chronic Myeloid Leukemia After Second‐Line Nilotinib: Enestop 5–Year Update,” Leukemia 35, no. 6 (2021): 1631–1642, 10.1038/s41375-021-01260-y. PubMed DOI

Mahon F. X., Boquimpani C., Kim D. W., et al. “Treatment‐Free Remission After Second‐Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single‐Group, Phase 2, Open‐Label Study,” Annals of Internal Medicine 168, no. 7 (2018): 461–470, 10.7326/m17-1094. PubMed DOI

Radich J. P., Hochhaus A., Masszi T., et al. “Treatment‐Free Remission Following Frontline Nilotinib in Patients With Chronic Phase Chronic Myeloid Leukemia: 5‐Year Update of the Enestfreedom Trial,” Leukemia 35, no. 5 (2021): 1344–1355, 10.1038/s41375-021-01205-5. PubMed DOI PMC

Hochhaus A., Masszi T., Giles F. J., et al. “Treatment‐Free Remission Following Frontline Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From the Enestfreedom Study,” Leukemia 31, no. 7 (2017): 1525–1531, 10.1038/leu.2017.63. PubMed DOI PMC

Kimura S., Imagawa J., Murai K., et al. “Treatment‐Free Remission After First‐Line Dasatinib Discontinuation in Patients With Chronic Myeloid Leukaemia (First‐Line DADI Trial): A Single‐Arm, Multicentre, Phase 2 Trial,” Lancet Haematology 7, no. 3 (2020): e218–e225, 10.1016/s2352-3026(19)30235-2. PubMed DOI

Clark R. E., Polydoros F., Apperley J. F., et al. “De‐Escalation of Tyrosine Kinase Inhibitor Therapy Before Complete Treatment Discontinuation in Patients With Chronic Myeloid Leukaemia (DESTINY): A Non‐Randomised, Phase 2 Trial,” Lancet Haematology 6, no. 7 (2019): e375–e383, 10.1016/s2352-3026(19)30094-8. PubMed DOI

Clark R. E., Polydoros F., Apperley J. F., et al. “De‐Escalation of Tyrosine Kinase Inhibitor Dose in Patients With Chronic Myeloid Leukaemia With Stable Major Molecular Response (DESTINY): An Interim Analysis of a Non‐Randomised, Phase 2 Trial,” Lancet Haematology 4, no. 7 (2017): e310–e316, 10.1016/s2352-3026(17)30066-2. PubMed DOI

Okada M., Imagawa J., Tanaka H., et al. “Final 3‐Year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second‐Line Treatment,” Clinical Lymphoma, Myeloma and Leukemia 18, no. 5 (2018): 353–360, 10.1016/j.clml.2018.03.004. PubMed DOI

Imagawa J., Tanaka H., Okada M., et al. “Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukaemia Who Have Maintained Deep Molecular Response for Longer than 1 Year (DADI Trial): A Multicentre Phase 2 Trial,” Lancet Haematology 2, no. 12 (2015): e528–e535, 10.1016/s2352-3026(15)00196-9. PubMed DOI

Etienne G., Guilhot J., Rea D., et al. “Long‐Term Follow‐Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia,” Journal of Clinical Oncology 35, no. 3 (2017): 298–305, 10.1200/jco.2016.68.2914. PubMed DOI

Mahon F.‐X., Réa D., Guilhot J., et al. and Intergroupe Français des Leucémies Myéloïdes Chroniques . “Discontinuation of Imatinib in Patients With Chronic Myeloid Leukaemia Who Have Maintained Complete Molecular Remission for at Least 2 Years: The Prospective, Multicentre Stop Imatinib (STIM) Trial,” Lancet Oncology 11, no. 11 (2010): 1029–1035, 10.1016/S1470-2045(10)70233-3. PubMed DOI

Rea D., Nicolini F. E., Tulliez M., et al. “Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia: Interim Analysis of the STOP 2G‐TKI Study,” Blood 129, no. 7 (2017): 846–854, 10.1182/blood-2016-09-742205. PubMed DOI

Lee S. E., Choi S. Y., Song H. Y., et al. “Imatinib Withdrawal Syndrome and Longer Duration of Imatinib Have a Close Association With a Lower Molecular Relapse After Treatment Discontinuation: The KID Study,” Haematologica 101, no. 6 (2016): 717–723, 10.3324/haematol.2015.139899. PubMed DOI PMC

Park J. S., Lee S. E., Jeong S. H., et al. “Change of Health‐Related Profiles After Imatinib Cessation in Chronic Phase Chronic Myeloid Leukemia Patients,” Leukemia and Lymphoma 57, no. 2 (2016): 341–347, 10.3109/10428194.2015.1049166. PubMed DOI

Lee S. E., Choi S. Y., Bang J. H., et al. “Predictive Factors for Successful Imatinib Cessation in Chronic Myeloid Leukemia Patients Treated With Imatinib,” American Journal of Hematology 88, no. 6 (2013): 449–454, 10.1002/ajh.23427. PubMed DOI

Ross D. M., Branford S., Seymour J. F., et al. “Safety and Efficacy of Imatinib Cessation for CML Patients With Stable Undetectable Minimal Residual Disease: Results From the TWISTER Study,” Blood 122, no. 4 (July 2013): 515–522, 10.1182/blood-2013-02-483750. PubMed DOI

Takahashi N., Kyo T., Maeda Y., et al. “Discontinuation of Imatinib in Japanese Patients With Chronic Myeloid Leukemia,” Haematologica 97, no. 6 (2012): 903–906, 10.3324/haematol.2011.056853. PubMed DOI PMC

Dulucq S., Astrugue C., Etienne G., Mahon F. X., and Benard A., “Risk of Molecular Recurrence After Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukaemia Patients: A Systematic Review of Literature With a Meta‐Analysis of Studies Over the Last Ten Years,” British Journal of Haematology 189, no. 3 (2020): 452–468, 10.1111/bjh.16408. PubMed DOI

Chomel J. C., Bonnet M. L., Sorel N., et al. “Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia Patients With Sustained Undetectable Molecular Residual Disease,” Blood 118, no. 13 (2011): 3657–3660, 10.1182/blood-2011-02-335497. PubMed DOI PMC

Cross N. C. P., Ernst T., Branford S., et al. “European Leukemianet Laboratory Recommendations for the Diagnosis and Management of Chronic Myeloid Leukemia,” Leukemia 37, no. 11 (November 2023): 2150–2167, 10.1038/s41375-023-02048-y. PubMed DOI PMC

Haferlach T., Winkemann M., Nickenig C., et al. “Which Compartments are Involved in Philadelphia‐Chromosome Positive Chronic Myeloid Leukaemia? An Answer at the Single Cell Level by Combining May‐Grünwald‐Giemsa Staining and Fluorescence in Situ Hybridization Techniques,” British Journal of Haematology 97, no. 1 (1997): 99–106, 10.1046/j.1365-2141.1997.9662656.x. PubMed DOI

Nicholas B. A., Purohit R., Woods A. D., et al. “BCR‐ABL is Enriched in S‐ and G2‐Cell Cycle Phases,” Leukemia Research 126 (2023): 107036, 10.1016/j.leukres.2023.107036. PubMed DOI

Graham S. M., Jørgensen H. G., Allan E., et al. “Primitive, Quiescent, Philadelphia‐Positive Stem Cells From Patients With Chronic Myeloid Leukemia are Insensitive to STI571 in Vitro,” Blood 99, no. 1 (2002): 319–325, 10.1182/blood.v99.1.319. PubMed DOI

Corbin A. S., Agarwal A., Loriaux M., Cortes J., Deininger M. W., and Druker B. J., “Human Chronic Myeloid Leukemia Stem Cells are Insensitive to Imatinib Despite Inhibition of BCR‐ABL Activity,” Journal of Clinical Investigation 121, no. 1 (2011): 396–409, 10.1172/jci46407. PubMed DOI PMC

Radich J. P., Gehly G., Gooley T., et al. “Polymerase Chain Reaction Detection of the BCR‐ABL Fusion Transcript After Allogeneic Marrow Transplantation for Chronic Myeloid Leukemia: Results and Implications in 346 Patients,” Blood 85, no. 9 (1995): 2632–2638, 10.1182/blood.v85.9.2632.bloodjournal8592632. PubMed DOI

Michor F., Hughes T. P., Iwasa Y., et al. “Dynamics of Chronic Myeloid Leukaemia,” Nature 435, no. 7046 (2005): 1267–1270, 10.1038/nature03669. PubMed DOI

Ross D. M., Branford S., Seymour J. F., et al. “Patients With Chronic Myeloid Leukemia Who Maintain a Complete Molecular Response After Stopping Imatinib Treatment Have Evidence of Persistent Leukemia by DNA PCR,” Leukemia 24, no. 10 (2010): 1719–1724, 10.1038/leu.2010.185. PubMed DOI

Pagani I. S., Dang P., Kommers I. O., et al. “ PubMed DOI PMC

Lenaerts T., Pacheco J. M., Traulsen A., and Dingli D., “Tyrosine Kinase Inhibitor Therapy Can Cure Chronic Myeloid Leukemia Without Hitting Leukemic Stem Cells,” Haematologica 95, no. 6 (2010): 900–907, 10.3324/haematol.2009.015271. PubMed DOI PMC

Stein A. M., Bottino D., Modur V., et al. “BCR‐ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells are Reduced During Imatinib Treatment,” Clinical Cancer Research 17, no. 21 (2011): 6812–6821, 10.1158/1078-0432.ccr-11-0396. PubMed DOI

Horn M., Glauche I., Müller M. C., et al. “Model‐Based Decision Rules Reduce the Risk of Molecular Relapse After Cessation of Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia,” Blood 121, no. 2 (2013): 378–384, 10.1182/blood-2012-07-441956. PubMed DOI

Claudiani S., Apperley J. F., Khan A., Khorashad J., and Milojkovic D., “Prolonged Treatment‐Free Remission in Chronic Myeloid Leukemia Patients With Previous BCR‐ABL1 Kinase Domain Mutations,” Haematologica 105, no. 5 (2020): e225–e227, 10.3324/haematol.2019.234179. PubMed DOI PMC

Žáčková D., Semerád L., Faber E., et al., “Why are Not all Eligible Chronic Myeloid Leukemia Patients Willing to Attempt Tyrosine Kinase Inhibitor Discontinuation? A Czech Nationwide Analysis Related to the TKI Stopping Trial HALF,” Leukemia 38, no. 4 (2024): 893–897, 10.1038/s41375-024-02215-9. PubMed DOI PMC

Shanmuganathan N., Braley J. A., Yong A. S. M., et al. “Modelling the Safe Minimum Frequency of Molecular Monitoring for CML Patients Attempting Treatment‐Free Remission,” Blood 134, no. 1 (2019): 85–89, 10.1182/blood.2019000120. PubMed DOI

Rousselot P., Charbonnier A., Cony‐Makhoul P., et al. “Loss of Major Molecular Response as a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic‐Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease,” Journal of Clinical Oncology 32, no. 5 (2014): 424–430, 10.1200/jco.2012.48.5797. PubMed DOI

Dulucq S., Nicolini F. E., Rea D., et al. “Kinetics of Early and Late Molecular Recurrences After First‐Line Imatinib Cessation in Chronic Myeloid Leukemia: Updated Results From the STIM2 Trial,” Haematologica 107, no. 12 (2022): 2859–2869, 10.3324/haematol.2022.280811. PubMed DOI PMC

Mori S., Vagge E., le Coutre P., et al. “Age and Dpcr can Predict Relapse in CML Patients Who Discontinued Imatinib: The ISAV Study,” American Journal of Hematology 90, no. 10 (2015): 910–914, 10.1002/ajh.24120. PubMed DOI

Atallah E., Schiffer C. A., Radich J. P., et al. “Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial,” JAMA Oncology 7, no. 1 (2021): 42–50, 10.1001/jamaoncol.2020.5774. PubMed DOI PMC

Laganà A., Scalzulli E., Carmosino I., et al. “Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse,” European Journal of Haematology 115, no. 4 (June 2025): 367–379: Epub ahead of print, 10.1111/ejh.70006. PubMed DOI

Claudiani S., Apperley J. F., Gale R. P., et al. “E14a2 PubMed DOI PMC

Johnson‐Ansah H., Charbonnier A., Etienne G., et al. “Treatment‐Free Remission in Chronic Myeloid Leukemia With Rare ABL1 Gene Fusions: Real‐Life Study From the French CML Group Fi‐LMC,” Leukemia Research 154 (2025): 107716, 10.1016/j.leukres.2025.107716. PubMed DOI

Kim D. D. H., Novitzky‐Basso I., Kim T. S., et al. “Optimal Duration of Imatinib Treatment/Deep Molecular Response for Treatment‐Free Remission After Imatinib Discontinuation From a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial,” British Journal of Haematology 193, no. 4 (2021): 779–791, 10.1111/bjh.17447. PubMed DOI

Nicolini F. E., Dulucq S., Boureau L., et al. “Evaluation of Residual Disease and TKI Duration are Critical Predictive Factors for Molecular Recurrence After Stopping Imatinib First‐Line in Chronic Phase CML Patients,” Clinical Cancer Research 25, no. 22 (2019): 6606–6613, 10.1158/1078-0432.ccr-18-3373. PubMed DOI

Kantarjian H. M., Hughes T. P., Larson R. A., et al. “Long‐Term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Enestnd 10‐Year Analysis,” Leukemia 35, no. 2 (2021): 440–453: Erratum in: Leukemia. 2021;35(7):2142‐2143, 10.1038/s41375-020-01111-2. PubMed DOI PMC

Claudiani S., Chee L., Fernando F., et al. “Treatment‐Free Remission in CML Patients With Additional Chromosome Abnormalities in the Philadelphia‐Positive Clone or Variant Philadelphia Translocations,” American Journal of Hematology 99, no. 6 (2024): 1172–1174, 10.1002/ajh.27278. PubMed DOI

Haddad F. G., Sasaki K., Issa G. C., Jabbour E., and Kantarjian H., “The Presence of Additional Cytogenetic Abnormalities (Acas) or Philadelphia Chromosome Variants Do Not Adversely Affect the Achievement of Treatment‐Free Remission in Chronic Myeloid Leukemia,” American Journal of Hematology 99, no. 6 (2024): 1175–1176, 10.1002/ajh.27307. PubMed DOI

Shanmuganathan N., Pagani I. S., Ross D. M., et al. “Early BCR‐ABL1 Kinetics are Predictive of Subsequent Achievement of Treatment‐Free Remission in Chronic Myeloid Leukemia,” Blood 137, no. 9 (2021): 1196–1207, 10.1182/blood.2020005514. PubMed DOI

Saugues S., Lambert C., Daguenet E., et al. “The Initial Molecular Response Predicts the Deep Molecular Response but Not Treatment‐Free Remission Maintenance in a Real‐World Chronic Myeloid Leukemia Cohort,” Haematologica 109, no. 9 (2024): 2893–2907, 10.3324/haematol.2023.284860. PubMed DOI PMC

Kim D. D. H., Kim T. S., Atenafu E. G., et al. “BCR‐ABL1 Transcript Doubling Time as a Predictor for Treatment‐free Remission Failure After Imatinib Discontinuation in Chronic Myeloid Leukaemia in Chronic Phase,” British Journal of Haematology 196, no. 1 (2022): 136–145, 10.1111/bjh.17807. PubMed DOI

Gottschalk A., Glauche I., Cicconi S., Clark R. E., and Roeder I., “Molecular Monitoring During Dose Reduction Predicts Recurrence After TKI Cessation in CML,” Blood 135, no. 10 (2020): 766–769, 10.1182/blood.2019003395. PubMed DOI

Pagani I. S., Shanmuganathan N., Dang P., et al. “Lineage‐Specific Detection of Residual Disease Predicts Relapse in Patients With Chronic Myeloid Leukemia Stopping Therapy,” Blood 142, no. 25 (2023): 2192–2197, 10.1182/blood.2023021119. PubMed DOI

Machova Polakova K., Zizkova H., Zuna J., et al. “Analysis of Chronic Myeloid Leukaemia During Deep Molecular Response by Genomic PCR: A Traffic Light Stratification Model With Impact on Treatment‐Free Remission,” Leukemia 34, no. 8 (2020): 2113–2124, 10.1038/s41375-020-0882-1. PubMed DOI

Lu L., Kok C. H., Dang P., et al. “Highly Sensitive Droplet Digital Polymerase Chain Reaction for BCR::ABL1 Messenger RNA Identifies Patients With Chronic Myeloid Leukaemia With a Low Probability of Achieving Treatment‐Free Remission,” British Journal of Haematology 198, no. 3 (2022): 600–603, 10.1111/bjh.18277. PubMed DOI

Kockerols C., Valk P. J. M., Janssen J. J. W. M., et al. “Prediction of Sustained Remission After Tyrosine Kinase Inhibitor Discontinuation With BCR::ABL1 Digital PCR in Chronic Myeloid Leukemia Patients,” European Journal of Haematology 113, no. 5 (2024): 606–613, 10.1111/ejh.14271. PubMed DOI

Clarkson B., Strife A., Wisniewski D., Lambek C. L., and Liu C., “Chronic Myelogenous Leukemia as a Paradigm of Early Cancer and Possible Curative Strategies,” Leukemia 17, no. 7 (2003): 1211–1262, 10.1038/sj.leu.2402912. PubMed DOI

Machova Polakova K., Albeer A., Polivkova V., et al. “The SNP rs460089 in the Gene Promoter of the Drug Transporter OCTN1 Has Prognostic Value for Treatment‐Free Remission in Chronic Myeloid Leukemia Patients Treated With Imatinib,” Leukemia 38, no. 2 (2024): 318–325, 10.1038/s41375-023-02109-2. PubMed DOI PMC

Rinaldetti S., Pfirrmann M., Manz K., et al. “Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment‐Free Remission in a EURO‐SKI Subtrial,” Clinical Lymphoma, Myeloma and Leukemia 18, no. 4 (2018): 266–271, 10.1016/j.clml.2018.02.004. PubMed DOI

Söderlund S., Persson I., Ilander M., et al. “Plasma Proteomics of Biomarkers for Inflammation or Cancer Cannot Predict Relapse in Chronic Myeloid Leukaemia Patients Stopping Tyrosine Kinase Inhibitor Therapy,” Leukemia Research 90 (2020): 106310, 10.1016/j.leukres.2020.106310. PubMed DOI

Kolb H. J., Mittermüller J., Clemm C., et al. “Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients,” Blood 76, no. 12 (1990): 2462–2465, 10.1182/blood.v76.12.2462.2462. PubMed DOI

Collins R. H. Jr, Shpilberg O., Drobyski W. R., et al. “Donor Leukocyte Infusions in 140 Patients With Relapsed Malignancy After Allogeneic Bone Marrow Transplantation,” Journal of Clinical Oncology 15, no. 2 (1997): 433–444, 10.1200/jco.1997.15.2.433. PubMed DOI

Decroos A., Meddour S., Demoy M., et al. “The CML Experience to Elucidate the Role of Innate T‐Cells as Effectors in the Control of Residual Cancer Cells and as Potential Targets for Cancer Therapy,” Frontiers in Immunology 15 (2024): 1473139, 10.3389/fimmu.2024.1473139. PubMed DOI PMC

Huuhtanen J., Adnan‐Awad S., Theodoropoulos J., et al. “Single‐Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation,” Leukemia 38, no. 1 (2024): 109–125, 10.1038/s41375-023-02074-w. PubMed DOI PMC

Kwaśnik P., Zaleska J., Link‐Lenczowska D., et al. “Level of CD8+PD‐1+ Cells in Patients With Chronic Myeloid Leukemia Who Experienced Loss of MMR After Imatinib Discontinuation,” Cells 13, no. 8 (2024): 723, 10.3390/cells13080723. PubMed DOI PMC

Ureshino H., Ueda Y., Fujisawa S., et al. “KIR3DL1‐HLA‐Bw Status in CML is Associated With Achievement of TFR: The POKSTIC Trial, a Multicenter Observational Study,” Blood Neoplasia 1, no. 1 (2024): 100001, 10.1016/j.bneo.2024.100001. PubMed DOI PMC

Irani Y. D., Kok C. H., Clarson J., et al. “Association of TIM‐3 Checkpoint Receptor Expression on T Cells With Treatment‐Free Remission in Chronic Myeloid Leukemia,” Blood Advances 7, no. 11 (2023): 2364–2374, 10.1182/bloodadvances.2022008854. PubMed DOI PMC

Irani Y. D., Hughes A., Clarson J., et al. “Successful Treatment‐Free Remission in Chronic Myeloid Leukaemia and Its Association With Reduced Immune Suppressors and Increased Natural Killer Cells,” British Journal of Haematology 191, no. 3 (2020): 433–441, 10.1111/bjh.16718. PubMed DOI

Austin G. M., Knight K., Bell J., et al. “The Effect on Lymphocyte Subsets of Decreasing/Stopping Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia: Data From the DESTINY Trial,” British Journal of Haematology 185, no. 4 (2019): 791–793, 10.1111/bjh.15629. PubMed DOI

Cayssials E., Jacomet F., Piccirilli N., et al. “Sustained Treatment‐free Remission in Chronic Myeloid Leukaemia is Associated With an Increased Frequency of Innate CD8(+) T‐Cells,” British Journal of Haematology 186, no. 1 (2019): 54–59, 10.1111/bjh.15858. PubMed DOI

Ilander M., Olsson‐Strömberg U., Schlums H., et al. “Increased Proportion of Mature NK Cells is Associated With Successful Imatinib Discontinuation in Chronic Myeloid Leukemia,” Leukemia 31, no. 5 (2017): 1108–1116, 10.1038/leu.2016.360. PubMed DOI PMC

Rea D., Henry G., Khaznadar Z., et al. “Natural Killer‐Cell Counts are Associated With Molecular Relapse‐free Survival After Imatinib Discontinuation in Chronic Myeloid Leukemia: The IMMUNOSTIM Study,” Haematologica 102, no. 8 (2017): 1368–1377, 10.3324/haematol.2017.165001. PubMed DOI PMC

Schütz C., Inselmann S., Saussele S., et al. “Expression of the CTLA‐4 Ligand CD86 on Plasmacytoid Dendritic Cells (Pdc) Predicts Risk of Disease Recurrence After Treatment Discontinuation in CML,” Leukemia 31, no. 4 (2017): 829–836: Erratum in: Leukemia. 2018;32(4):1054, 10.1038/leu.2017.9. PubMed DOI

Caocci G., Martino B., Greco M., et al. “Killer Immunoglobulin‐Like Receptors can Predict TKI Treatment‐Free Remission in Chronic Myeloid Leukemia Patients,” Experimental Hematology 43, no. 12 (2015): 1015–1018.e1, 10.1016/j.exphem.2015.08.004. PubMed DOI

Richter J., Söderlund S., Lübking A., et al. “Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?,” Journal of Clinical Oncology 32, no. 25 (2014): 2821–2823, 10.1200/JCO.2014.55.6910. PubMed DOI

Katagiri S., Tauchi T., Ando K., et al., “Low Body Weight and Body Mass Index May Be Associated With Musculoskeletal Pain Following Imatinib Discontinuation in Chronic Myeloid Leukemia,” Leukemia Research Reports 7 (2017): 33–35, 10.1016/j.lrr.2017.04.002. PubMed DOI PMC

Berger M. G., Pereira B., Rousselot P., et al. “Longer Treatment Duration and History of Osteoarticular Symptoms Predispose to Tyrosine Kinase Inhibitor Withdrawal Syndrome,” British Journal of Haematology 187, no. 3 (2019): 337–346, 10.1111/bjh.16083. PubMed DOI

Rix U., Hantschel O., Dürnberger G., et al. “Chemical Proteomic Profiles of the BCR‐ABL Inhibitors Imatinib, Nilotinib, and Dasatinib Reveal Novel Kinase and Nonkinase Targets,” Blood 110, no. 12 (2007): 4055–4063, 10.1182/blood-2007-07-102061. PubMed DOI

Rousselot P., Loiseau C., Delord M., Cayuela J. M., and Spentchian M., “Late Molecular Recurrences in Patients With Chronic Myeloid Leukemia Experiencing Treatment‐Free Remission,” Blood Advances 4, no. 13 (2020): 3034–3040, 10.1182/bloodadvances.2020001772. PubMed DOI PMC

Richter J., Lübking A., Söderlund S., et al. “Molecular Status 36 Months After TKI Discontinuation in CML is Highly Predictive for Subsequent Loss of MMR‐Final Report From AFTER‐SKI,” Leukemia 35, no. 8 (2021): 2416–2418, 10.1038/s41375-021-01173-w. PubMed DOI PMC

Katagiri S., Gotoh A., and Ohyashiki K., “Very Late Relapse With Rapid BCR‐ABL1 Elevation After More Than Seven Years of Treatment‐Free Remission With Undetectable Molecular Residual Disease in Chronic Myeloid Leukaemia,” British Journal of Haematology 188, no. 2 (2020): 332–334, 10.1111/bjh.16285. PubMed DOI

Ross D. M., Pagani I. S., Shanmuganathan N., et al. “Long‐Term Treatment‐Free Remission of Chronic Myeloid Leukemia With Falling Levels of Residual Leukemic Cells,” Leukemia 32, no. 12 (2018): 2572–2579, 10.1038/s41375-018-0264-0. PubMed DOI

Zambrotta G. P. M., Nicolini F. E., Assouline S., et al. “Risk of Progression in Chronic Phase‐Chronic Myeloid Leukemia Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: Final Analysis of the TFR‐PRO Study,” American Journal of Hematology 98, no. 11 (2023): 1762–1771, 10.1002/ajh.27073. PubMed DOI

Alfayez M., Richard‐Carpentier G., Jabbour E., et al. “Sudden Blastic Transformation in Treatment‐Free Remission Chronic Myeloid Leukaemia,” British Journal of Haematology 187, no. 4 (2019): 543–545, 10.1111/bjh.16245. PubMed DOI

Bataller A., Haddad F. G., Issa G. C., et al. “Sudden Lymphoid Blast Crisis After Tyrosine Kinase Inhibitor Discontinuation in Chronic Phase Chronic Myeloid Leukemia: Cautionary Tales for Appropriate Molecular Monitoring,” Leukemia and Lymphoma 64, no. 3 (2023): 746–749, 10.1080/10428194.2023.2165395. PubMed DOI

Liang Q., Liu Z., Wu Y., Zhu H., and Yang Y., “Sudden Blast Crisis in a Chronic Myeloid Leukemia Patient in Treatment‐free Remission: A Case Report and Literature Review,” Acta Haematologica 148, no. 4 (2025): 371–379, 10.1159/000542153. PubMed DOI

Papalexandri A., Saloum R., Touloumenidou T., et al. “Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?,” Hemasphere 2, no. 6 (2018): e157, 10.1097/hs9.0000000000000157. PubMed DOI PMC

Dulucq S., Hayette S., Cayuela J. M., et al. “Onset of Blast Crisis in Chronic Myeloid Leukemia Patients in Treatment‐Free Remission,” Haematologica 107, no. 12 (2022): 2944–2949, 10.3324/haematol.2022.280740. PubMed DOI PMC

Steegmann J. L., Baccarani M., Breccia M., et al. “European Leukemianet Recommendations for the Management and Avoidance of Adverse Events of Treatment in Chronic Myeloid Leukaemia,” Leukemia 30, no. 8 (2016): 1648–1671, 10.1038/leu.2016.104. PubMed DOI PMC

Lipton J. H., Brümmendorf T. H., Gambacorti‐Passerini C., Garcia‐Gutiérrez V., Deininger M. W., and Cortes J. E., “Long‐Term Safety Review of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia ‐ What to Look for When Treatment‐Free Remission is Not an Option,” Blood Reviews 56 (2022): 100968, 10.1016/j.blre.2022.100968. PubMed DOI

Efficace F., Mahon F. X., Richter J., et al. “Health‐Related Quality of Life and Symptoms of Chronic Myeloid Leukemia Patients After Discontinuation of Tyrosine Kinase Inhibitors: Results From the EURO‐SKI Trial,” Leukemia 38, no. 8 (2024): 1722–1730, 10.1038/s41375-024-02341-4. PubMed DOI

Mayer J., Machová‐Poláková K., Karas M., et al., “Chronic Myeloid Leukemia (CML) Treatment Discontinuation After a Two‐Step Dose Reduction. The First Results of the Phase 2 Study HALF,” HemaSphere 9, no. S1 (2025): 159–160, https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70151. DOI

Racil Z., Koritakova E., Sacha T., et al. “Insulin Resistance is an Underlying Mechanism of Impaired Glucose Metabolism During Nilotinib Therapy,” American Journal of Hematology 93, no. 10 (2018): E342–E345, 10.1002/ajh.25232. PubMed DOI

Smit Y., Metsemakers S. J. J. P. M., Janssen J. J. W. M., et al. “Measuring Chronic Myeloid Leukaemia TKI‐Related Toxic Effects in the Real World: A Systematic Review and Critical Assessment of Content Validity of Patient‐Reported Outcome Measures,” Lancet Haematology 10, no. 10 (2023): e849–e859, 10.1016/s2352-3026(23)00173-4. PubMed DOI

Kantarjian H., Breccia M., Haddad F. G., et al. “Management of Chronic Myeloid Leukemia in 2025,” Cancer 131, no. 14 (2025): e35953, 10.1002/cncr.35953. PubMed DOI PMC

Cortes J. E., Saglio G., Kantarjian H. M., et al. “Final 5‐year Study Results of DASISION: The Dasatinib Vesrus Imatinib Study in Treatment–Naïve Chronic Myeloid Leukemia Patients,” Journal of Clinical Oncology 34, no. 20 (2016): 2333–2340, 10.1200/jco.2015.64.8899. PubMed DOI PMC

Kantarjian H. M., Hughes T. P., Larson R. A., et al. “Long‐Term Outcomes With Frontline Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Enestnd 10‐Year Analysis,” Leukemia 35, no. 2 (2021): 440–453, 10.1038/s41375-020-01111-2. PubMed DOI PMC

Brümendorf T. H., Cortes J. E., Milojkovic D., et al. “Bosutinib Versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final Results From the BFORE Trial,” Leukemia 36, no. 7 (2022): 1825–1833, 10.1038/s41375-022-01589-y. PubMed DOI PMC

Hochhaus A., Wang J., Kim D.‐W., et al. “Asciminib in Newly Diagnosed Chronic Myeloid Leukemia,” New England Journal of Medicine 391, no. 10 (2024): 885–898, 10.1056/nejmoa2400858. PubMed DOI

Laganà A., Scalzulli E., Bisegna M. L., et al. “Treatment Free Remission (TFR) After Second‐Generation Tyrosine Kinase Inhibitors (2G‐TKIs) Treatment in Chronic Myeloid Leukemia (CML): From Feasibility to Safety,” Expert Opinion on Drug Safety 23, no. 8 (2024): 969–979, 10.1080/14740338.2024.2368822. PubMed DOI

Costa A. and Breccia M., “How to Improve Treatment‐Free Remission Eligibility in Chronic Myeloid Leukaemia?,” British Journal of Haematology 204, no. 2 (2024): 434–448, 10.1111/bjh.19269. PubMed DOI

Breccia M., Castagnetti F., Piciocchi A., et al., “SUSTRENIM Trial: Sustained Deep Molecular Response and TFR Rate in the Long‐Term Follow‐Up,” HemaSphere 8, no. S1 (2024): 152–153, https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.104. DOI